[
  {
    "info": {
      "NCT": "NCT02912949",
      "Protocol_No": "MCLA-128-CL01",
      "jit": "Tempus",
      "trial_name": "Merus eNRGy"
    },
    "disease": {
      "summary": "Solid Tumors| NSCLC LUNG | Pancreatic Cancer | NRG1 Fusion",
      "details": [
        {
          "code": "Non-Small Cell Lung Cancer (NSCLC)",
          "selection": "include",
          "stage": "Advanced Stage"
        },
        {
          "code": "Pancreatic Adenocarcinoma (PAAD)",
          "selection": "include",
          "stage": "Advanced Stage"
        },
        {
          "code": "Solid Tumors",
          "selection": "include",
          "stage": "Un-resectable;Advanced Stage;Metastatic"
        }
      ]
    },
    "query": {
      "nct": "NCT02912949",
      "title": "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)",
      "current_status": "Recruiting",
      "status_verif_date": "August 2022",
      "last_update_date": "August 10, 2022",
      "trial_hold_status": "open (JIT)",
      "sponsor": "Merus N.V.",
      "brief_summary": "This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)",
      "conditions": "Solid Tumours Harboring NRG1 Fusion | NSCLC Harboring NRG1 Fusion | Pancreatic Cancer Harboring NRG1 Fusion | NRG1 Fusion",
      "type": "Interventional",
      "phase": "Phase 2",
      "arm": [
        {
          "ArmID": "1",
          "cohortlabel": "Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion",
          "drug": "zenocutuzumab (MCLA-128)",
          "arm_type": "Experimental",
          "line_of_therapy": "2+",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Part 2 Pancreatic adenocarcinoma harboring NRG1 fusion",
              "Gene": "NRG1",
              "Gene2": "NRG1",
              "Type": "Fusion",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "NRG1-NRG1 Fusion"
            }
          ]
        },
        {
          "ArmID": "2",
          "cohortlabel": "Part 2 NSCLC cancer harboring NRG1 fusion",
          "drug": "zenocutuzumab (MCLA-128)",
          "arm_type": "Experimental",
          "line_of_therapy": "2+",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Part 2 NSCLC cancer harboring NRG1 fusion",
              "Gene": "NRG1",
              "Gene2": "NRG1",
              "Type": "Fusion",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "NRG1-NRG1 Fusion"
            }
          ]
        },
        {
          "ArmID": "3",
          "cohortlabel": "Part 2 Solid tumour (basket) harboring NRG1 fusion",
          "drug": "zenocutuzumab (MCLA-128)",
          "arm_type": "Experimental",
          "line_of_therapy": "2+",
          "arm_hold_status": "open",
          "biomarker": [
            {
              "cohort": "Part 2 Solid tumour (basket) harboring NRG1 fusion",
              "Gene": "NRG1",
              "Gene2": "NRG1",
              "Type": "Fusion",
              "Variant": "Not available",
              "Selection": "include",
              "Function": "Not available",
              "summary": "NRG1-NRG1 Fusion"
            }
          ]
        }
      ],
      "docs": "<a href=\"https://therapies.securetempus.com/\" target=\"_blank\">Tempus<\/a>",
      "locations": "Sioux Falls SD",
      "doclastupdate": "2023-01-30",
      "min_age": "18 Years",
      "gender": "All",
      "link": "<a href=\"https://clinicaltrials.gov/ct2/show/NCT02912949\" target=\"_blank\">NCT02912949<\/a>"
    }
  }
]
